165 related articles for article (PubMed ID: 19958868)
1. Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial.
Hermiller JB; Fergus T; Pierson W; Su X; Sood P; Sudhir K; Stone GW
Am Heart J; 2009 Dec; 158(6):1005-10. PubMed ID: 19958868
[TBL] [Abstract][Full Text] [Related]
2. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW
Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147
[TBL] [Abstract][Full Text] [Related]
3. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
[TBL] [Abstract][Full Text] [Related]
4. An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials.
Bartorelli AL; Serruys PW; Miquel-Hébert K; Yu S; Pierson W; Stone GW;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):60-6. PubMed ID: 20578194
[TBL] [Abstract][Full Text] [Related]
5. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of XIENCE V everolimus-eluting and Taxus Express2 paclitaxel-eluting coronary stents in patients with jailed side branches from the SPIRIT IV trial at 2 years.
Forrest JK; Lansky AJ; Meller SM; Hou L; Sood P; Applegate RJ; Wang JC; Skelding KA; Shah A; Kereiakes DJ; Sudhir K; Cristea E; Yaqub M; Stone GW
Am J Cardiol; 2013 Jun; 111(11):1580-6. PubMed ID: 23499270
[TBL] [Abstract][Full Text] [Related]
7. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease. Study design and rationale of the EXECUTIVE trial.
Ribichini F; Ansalone G; Bartorelli A; Beqaraj F; Berni A; Colangelo S; D'Amico M; Della Rovere F; Fiscella A; Gabrielli G; Indolfi C; La Vecchia L; Loschiavo P; Marinoni G; Marzocchi A; Milazzo D; Romano M; Sangiorgio P; Sheiban I; Tamburino C; Tuccillo B; Villani R; Cappi B; Quijada MJ; Vassanelli C;
J Cardiovasc Med (Hagerstown); 2010 Apr; 11(4):299-309. PubMed ID: 20090550
[TBL] [Abstract][Full Text] [Related]
8. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
9. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
11. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
[TBL] [Abstract][Full Text] [Related]
12. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
[TBL] [Abstract][Full Text] [Related]
13. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial).
Applegate RJ; Yaqub M; Hermiller JB; Sood P; Yu S; Doostzadeh J; Williams JE; Farhat N; Caputo R; Lansky AJ; Cutlip DE; Sudhir K; Stone GW
Am J Cardiol; 2011 Mar; 107(6):833-40. PubMed ID: 21247538
[TBL] [Abstract][Full Text] [Related]
14. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Mahaffey KW; Cutlip DE; Fitzgerald PJ; Sood P; Su X; Lansky AJ;
JAMA; 2008 Apr; 299(16):1903-13. PubMed ID: 18430909
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
16. Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial).
Ng VG; Lansky AJ; Hermiller JB; Farhat N; Applegate RJ; Yaqub M; Sood P; Su X; Simonton CA; Sudhir K; Stone GW
Am J Cardiol; 2011 Mar; 107(6):841-8. PubMed ID: 21255760
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous coronary intervention with everolimus-eluting stents (Xience V): systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher).
Biondi-Zoccai G; Lotrionte M; Moretti C; Agostoni P; Sillano D; Laudito A; Sheiban I
Minerva Cardioangiol; 2008 Feb; 56(1):55-65. PubMed ID: 18432169
[TBL] [Abstract][Full Text] [Related]
18. Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry.
Gordon PC; Applegate RJ; Hermiller JB; Weinsier SB; Doostzadeh J; Cao S; Sudhir K; Lansky AJ; Stone GW
Catheter Cardiovasc Interv; 2010 Feb; 75(2):179-86. PubMed ID: 19877267
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial.
Applegate R; Hermiller J; Williams J; Gordon P; Doostzadeh J; Cao S; Su X; Sudhir K; Lansky A; Simonton C; Stone G
Catheter Cardiovasc Interv; 2010 Nov; 76(5):644-51. PubMed ID: 20506356
[TBL] [Abstract][Full Text] [Related]
20. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions.
Grube E; Chevalier B; Guagliumi G; Smits PC; Stuteville M; Dorange C; Papeleu P; Kaul U; Džavík V
Am Heart J; 2012 May; 163(5):867-875.e1. PubMed ID: 22607866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
